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Abstract 
The incidence and prevalence of non-communicable disease is increasing. 
Preliminary evidence suggests that benefits of cardiovascular rehabilitation (CR) 
participation are observed in patients with stroke and diabetes (vascular diseases). The 
objectives were to compare outcomes of patients whose primary CR indication was 
cardiac (CD) versus vascular disease following initiation of CR. 
Participants were recruited through a multi-site program evaluation at :four CR 
programs. Consenting participants completed a survey pre-program and again 6 months 
later. Clinical data were extracted from patients' charts at both time points. 
CD patients were significantly more likely to complete CR. CD patients who 
attended CR significantly improved their activity status, exercise behavior and nutrition. 
Vascular disease patients who attended CR significantly improved their physical activity. 
This practical examination of integrated chronic disease management provides 
preliminary support for the benefits of CR for vascular disease patients, but attention to 
meeting their unique needs to ensure full participation may be needed. 
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Introduction 
Cardiovascular diseases (CVD) are among the leading causes of death and 
disability around the world, including in Canada 1• CVDs are disorders that primary affect 
the heart and blood vessels, including in the brain and legs. Risk factors are common with 
various CVDs affecting different parts of the body1• Having multiple blood vessels 
affected increases the risk of adverse outcomes, and management is more complex2- 5• 
Cardiac Rehabilitation (CR) is a multidisciplinary approach to secondary 
prevention that includes exercise training, education, and counselling for both client and 
family6. CR is a well-established secondary prevention program model that is 
increasingly being offered to patients with other vascular diseases. Preliminary research 
suggests it is safe and feasible for patients with various vascular diseases, and that they 
can derive similar benefit as cardiac patients7- 9• Indeed, the recently-released Ontario 
Integrated Vascular Health Strategy recommends such integrated chronic disease 
management. Accordingly, the objective of this thesis is to compare the outcomes of 
patients whose primary CR indication is cardiac versus other or poly-vascular disease 
(PolyVD) following program participation at several programs in Ontario. 
Review of Literature 
CVD is defined as a group of disorders affecting the circulatory system including 
the function and structure of the heart and blood vessels1•10•11 • Coronary artery disease 
(CAD) is defined as a progressive narrowing of the three main arteries (and their 
branches) that supply blood to the heart12• The narrowing and blockage of these arteries 
deprives the myocardium of rich oxygenated blood that is required for proper function 
thus causing various symptoms, such as angina (chest paint) and/or dyspnea (a shortness 
ofbreath)10•12• Complete blockage deprives the myocardium of oxygenated blood causing 
damage or death of the myocardium tissue, which is referred to as myocardial infarction 
(heart attack)1•10•11 • Cerebrovascular disease or stroke is defined as a disease of the blood 
vessels which are supplying the brain with oxygenated blood1•10•13• A ischemic stroke 
refers to a blockage caused by a built up of fatty deposits, whereas hemorrhagic stroke 
refers to a rupture of blood vessels within the brain causing the affected area of brain 
cells to die10•13• Peripheral vascular disease (PVD) is defined as a disease affecting the 
blood vessels supplying the extremities (arms and legs)1•10• Diabetes is defined as a 
chronic disease that occurs when the body does not manage insulin effectively14•15• This 
occurs when the pancreas does not produce sufficient insulin (Type 1 diabetes) or when 
the body does not use the insulin efficiently that has been produced (Type 2 diabetes), or 
gestational diabetes which occurs in women during pregnancy14•15• Renal disease 
(interchangeably used with Kidney disease) is defined as damage or loss of proper 
function to eliminate wastes and excess fluids from the body by the kidneys for a period 
of 3 months or longer16•17• PolyVD is defined as having disease in multiple arterial 
territories 3, and as such the co-existence of CVD, PVD and/or CAD2•3•5• 
Vascular Diseases 
Globally, the incidence and prevalence of CVDs was estimated to be 17.3 million 
people in 2008, of which for 7 .3 million people this was attributed to coronary heart 
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disease1• Stroke accounted for 6.2 million of all the CVD deaths1, while stroke survivors 
account for 300,000 individuals living with disability currently in Canada and this 
number will keep rising18• Furthermore, 1.3 million deaths in 2008 were directly related 
to diabetes1• In Canada, 28.7% (68,342) of deaths in 2009 were due to CVD; of the 
28.7% 121 deaths were due to renal disease, 14,105 were due to cerebrovascular disease, 
and 6,923 were due to diabetes mellitus19• However, due to advances in therapies, deaths 
due to CVD have declined by 25% over the past 10 years, resulting in many Canadians 
living with CVDs. As of 2008/09 in Canada, approximately 6.8% (2.4 million) 
individuals are living with diabetes and the prevalence is more than 200,000 individuals 
each year20• Individuals living with diabetes have a threefold increase of being 
hospitalized with CVD in comparison to individuals without diabetes, a twelvefold 
increase to be hospitalized with renal disease, and almost twentyfold increase to be 
hospitalized with lower limb amputations20• 
The prevalence of Poly VD ranges from 15.9-27.7%5, which also indicates that 
there is increased risk of poor health outcomes in patients with poly VD. Patients with 
PolyVD are at 15-30% increased risk of experiencing adverse cardiovascular events in 
comparison to patients with monovascular diseases. In particular, there is a 5-fold 
increased risk of stroke for Poly VD patients in comparison to patients with acute 
coronary syndrome (ACS)2• These patients generally have more poorer outcomes both in-
hospital and 6-months later in comparison to patients with mono vascular diseases. 
Vascular diseases have a common etiology, such as atherosclerosis, smoking, 
diabetes mellitus, hypertension, hypercholesterolemia, obesity, family history, and renal 
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failure2•5• Consequently, chronic vascular diseases also have common risk factors. The 
World Health Organization (WHO) identifies high blood pressure, abnormal blood lipids, 
tobacco use, physical inactivity, obesity, unhealthy diet and diabetes mellitus as major 
risk factors for CVD and stroke1•21 • Hazard increase when these risk factors co-occur 
(which is known as metabolic syndrome), as the risk of any one of CVD, stroke and 
diabetes becomes even greater22•23 • Risk factors increase the risk of initial and recurrence 
of events, but this is of greater concern for individuals with polyvascular disease2- 5•24• 
If these risk factors are not identified, reduced and controlled, patients have an 
increased risk of developing recurrent or more severe vascular disease. For example, 
patients with diabetes and renal disease who engage in regular exercise, and maintain a 
healthy diet lower their risk of heart disease and stroke21 .25- 27• In particular, Poly VD 
patients are at increased need for secondary prevention. However, there is little guidance 
on how to best manage these patients28, and evidence suggests they are managed less 
aggressively29• A multi-faceted approach is necessary to mitigate the progression of 
disease, through education, lifestyle modification (i.e., healthy eating, exercise, smoking 
cessation), evidence-based medication prescription, titration and monitoring, blood 
glucose control, and psychosocial support5•6• These interventions are available in chronic 
disease management programs, such as CR. 
Integrated Vascular Disease Management 
The Canadian Association of Cardiac Rehabilitation (CACR) defines CR as "the 
enhancement and maintenance of cardiovascular health through individualized programs 
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designed to optimize physical, psychological, social, vocational and emotional status. 
This process includes the facilitation and delivery of secondary prevention through heart 
hazard identification and modification, in an effort to prevent disease progression and 
recurrence of cardiac events"6• Exercise is the core component of this multidisciplinary 
approach to secondary prevention, which also include health behaviour change and 
education, lifestyle risk factor management (physical activity and exercise, diet, and 
smoking), psychosocial health, medical risk factor management, cardioprotective 
therapies, long-term management, and audit and evaluation30• In Ontario, the average CR 
program is of 5 months duration, and supervised exercise sessions are offered to patients 
twice per week31 • 
CR has been shown to significantly reduce cardiac risk, decrease the recurrence of 
cardiac events, and decrease mortality by 25%6•32• In the most recent Cochrane review, 
reduced hospital readmission rates were observed in the 6-12 months following CR when 
compared to patients not participating, and significantly reduced mortality was observed 
beyond 12 months post-CR32• Other benefits of CR include increased functional capacity, 
improved psychosocial well-being, greater rate of smoking cessation, improved blood 
lipid profile, and reduced hypertension33- 35 • These benefits of CR are substantiated 
amongst cardiac patients; it is unknown how many of these patients have other vascular 
diseases. However, given that approximately 15-30% cardiac patients have other vascular 
diseases5, it is likely that poly VD patients similarly benefit from CR. This remains to be 
explicitly investigated, as does the outcome of patients with disease in non-cardiac 
vascular beds? 
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Indeed there is some preliminary research investigating the effects of CR for 
stroke patients, and much of this work comes from Ontario. The CR model of exercise-
based secondary prevention may apply to stroke patients, as they are shown to benefit 
from fitness training as well36• Using this traditional CR model, the facilities and 
expertise in cardiovascular risk management through education and exercise can provide 
support for mild to moderate stroke survivors7• For instance, Prior et al. demonstrated that 
comprehensive CR is safe for patients post-TIA or mild non-disabling stroke8• Not only 
was it feasible for stroke patients to participate in CR, but it also resulted in significant 
improvements in V02peak, functional capacity and reduced depressive symptoms 7•9• 
Additionally, guidelines on diabetes and cardiovascular disease from the 
European Society of Cardiology and the European Association for the Study of Diabetes 
emphasize the importance of regular physical exercise and the association of reduced 
CVD as well as, total mortality for those patients with diabetes who regularly exercise37 • 
Furthermore, some preliminary findings suggest that patients with diabetes will benefit 
from CR with an aggressive program approach to risk factor management38•39• A 
traditional CR model can accommodate this unique patient population by improving 
functional capacity and management of fasting blood glucose, which is an important 
factor in improvement of V02peak38•39• 
Similar comprehensive outpatient disease management programs are not offered 
for stroke, diabetes, renal, and PVD patients. For instance, there are established inpatient 
rehabilitation facilities for stroke patients, but once they are discharged home, there are 
no disease management services offered. Moreover, there are many outpatient diabetes 
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education centers focused on nutrition and blood glucose control, but these do not address 
other risk factors or offer supervised exercise. Similarly, there are some outpatient dietary 
education offerings for renal patients, but we are not aware of any interprofessional 
programs with supervised exercise facilities. Given the commonalities in etioliogy and 
disease management, Ontario recently developed an Integrated Vascular Health Blueprint 
(http://www.opha.on.ca/Integrated%20Vascular%20Health%20Blueprint%20for%200nt 
ario August%202012.pdf), in an attempt to breakdown artificial barriers that may lie 
between these vascular diseases and their associated organizations. Their goal is to create 
a systematic, comprehensive approach that: promotes and protects the vascular health of 
Ontarians; ensures equitable and effective vascular health diagnosis, treatment and 
recovery; improves the models of healthcare delivery to better prepare Ontario for the 
growing number of seniors and potential increases in vascular patients; and reduces 
avoidable vascular morbidity and mortality40• Certainly, integrated vascular disease 
management is a key area of opportunity to realize this vision, and this is recognized by 
the Ontario Stroke Network and Cardiac Care Network of Ontario. Indeed, 62.2% of CR 
programs in Ontario already offer their services for chronic disease management to 
patients with non-cardiac indications31 • 
7 
Objectives 
The objectives of the study were to compare the outcomes of patients whose 
primary CR indication was cardiac (CD) versus other- or poly-vascular disease following 
initiation of an integrated vascular disease management program (CR). First, this thesis 
examined changes from pre- to post-CR in participants' risk factors (Body Mass Index 
(BMI), Waist Circumference (WC), Lipids, Blood pressure, HbAlc), functional status 
(V02 Max, METs), psychosocial well-being (depressive symptoms, quality oflife), and 
health behaviours (smoking status, nutrition habits, exercise, medication adherence) in 
CD vs vascular disease patients. It was hypothesized that significant improvements in all 
parameters would be observed in both CD and vascular disease patients. 
Second, this thesis compared CR wait times, the type of CR program attended (on 
site vs home-based), exercise self-efficacy, barriers to CR, degree of CR participation and 
completion, and patient perceptions of their chronic disease care in CD vs vascular 
disease patients who initiated CR. It was hypothesized that there would be no significant 
differences in these parameters by indication. 
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Manuscript Preface 
The thesis is prepared in manuscript format. The manuscript investigated: (1) CR 
utilization by clinical indication, (2) the sociodemographic and clinical characteristics of 
vascular disease patients who participate in CR versus those who do not, and (3) change 
in risk factors, functional capacity, psychosocial well-being and health behaviours from 
pre to post-program in cardiac vs vascular disease patients who participated in CR. The 
other objectives of the thesis are reported in the extended results and discussion section. 
Participants were recruited through a multi-site program evaluation at four CR 
programs in the Greater Toronto Area. Participants clinical characteristics were extracted 
pre and post CR (Appendix C & D). Participants completed a self-report survey pre and 
post CR that includes sociodemographic characteristics (see Appendix E), functional 
capacity indicators (see Appendix F), assessment of exercise behaviour (see Appendix 
G), nutrition habits (see Appendix H), medication adherence (see Appendix I), smoking 
status (see Appendix J), mood (see Appendix K), and quality of life (see Appendix L). A 
modified Dillman41 method was applied to optimize response rate, including a repeat 
email to non-responders (see Appendix U) and a telephone call (see Appendix V). The 
results of this study are presented in the manuscript which follows. 
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Abstract 
Introduction: The incidence and prevalence of non-communicable disease is increasing. 
Preliminary evidence suggests that benefits of cardiovascular rehabilitation (CR) 
participation are also observed in patients with stroke and diabetes (vascular diseases). 
This study compared: (1) CR utilization by clinical indication, (2) sociodemographic and 
clinical characteristics of vascular disease patients who participate in CR versus those 
who do not, and (3) change in risk factors, functional capacity, psychosocial well-being 
and health behaviours from pre to post-program in cardiac vs vascular disease patients 
who participated in CR. 
Methods: As part of a multi-site study, new CR patients were approached and asked to 
complete a survey pre-program and again 6 months later. The surveys included the Duke 
Activity Status Index, Godin Leisure-Time Exercise Questionnaire, Morisky Medication 
Adherence Survey, and Patient Health Questionnaire. Clinical data including risk factors 
and exercise test results were extracted from patient's charts at both time points. 
Results: Overall, 237 (84.0%) completed the pre-CR survey, and 201 (84.8%) 
completed the final survey. Cardiac patients (n=104, 68.9%) were significantly more 
likely to complete CR than vascular disease patients (n=37, 54.4%; p=0.039). Vascular 
disease patients who enrolled in CR engaged in more physical activity pre-program 
(p<.05). CD patients who attended CR achieved significant improvements in activity 
status, exercise behavior and nutrition by post-test (p<.01). Among vascular disease 
patients, there were trends toward lower depressive symptoms and greater exercise in 
those who participated in CR by post-test. 
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Conclusions: This practical examination of integrated chronic disease management 
provides preliminary support for the benefits of CR for other vascular patients. 
13 
Vascular diseases are defined as a group of disorders affecting the circulatory 
system as well as the function and structure of the heart, brain, and kidneys 1• 
Accordingly, these diseases include stroke, peripheral artery disease, coronary artery 
disease, renal artery disease, and diabetes mellitus. Their incidence and prevalence is 
high, such that cardiovascular diseases for example are among the leading causes of 
morbidity and mortality2. Globally, the incidence and prevalence of cardiovascular 
disease was estimated to be 17 .3 million people in 2008. With regard to mortality that 
same year, stroke accounted for 6.2 million deaths, with 1.3 million deaths directly 
related to diabetes2• 
Polyvascular disease (PolyVD) refers to disease in multiple arterial territories3, 
such as the co-existence of coronary artery and renal disease3- 5• The prevalence of 
PolyVD ranges from 15.9-27.7%5 among those with monovascular disease. PolyVD 
patients are at 15-30% increased risk of experiencing adverse cardiovascular events in 
comparison to patients with monovascular disease5• Despite this increased need for 
secondary prevention, there is little guidance on how to best manage PolyVD patients6, 
and evidence suggests they are managed less aggressively7. 
Vascular diseases have a common etiology, namely atherosclerosis4•5• 
Accordingly, they also have common risk factors such as hypertension, 
hypercholesterolemia, tobacco use, physical inactivity, obesity, and unhealthy diet2•8• A 
multi-faceted approach is necessary to mitigate the progression of vascular diseases, 
through education, lifestyle modification (i.e., healthy eating, exercise, smoking 
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cessation), evidence-based medication prescription, titration and monitoring, blood 
glucose control, and psychosocial support5•9• These interventions are available in chronic 
disease management programs, such as cardiovascular rehabilitation (CR). Indeed, CR 
has been shown to significantly reduce cardiac risk, decrease the recurrence of cardiac 
events, and decrease mortality by 25%9•10• Other benefits of CR include increased 
functional capacity, improved psychosocial well-being, greater smoking cessation, 
improved blood lipid profile, and reduced blood pressure1 I-13• 
While the benefits of CR are substantiated in the cardiac population, given that 
approximately 15-30% cardiac patients have other com orb id vascular diseases5, it is 
likely that these other clinical indications are ameliorated through CR. Indeed, the CR 
model of exercise-based secondary prevention has been recently applied to stroke 
patients, as they are shown to benefit from fitness training as well 14• For instance, Prior et 
al. demonstrated that comprehensive CR is safe for patients post-transient ischemic attack 
or mild non-disabling stroke15• Not only was it feasible for stroke patients to participate 
in CR, it also resulted in significant improvements in functional capacity and reduced 
depressive symptoms16•17• Moreover, emerging evidence supports the beneficial role of 
exercise training for renal patients 18• Yet, comprehensive outpatient disease management 
programs similar to CR are not available for stroke, diabetes, renal, or PVD patients. For 
instance, there are established inpatient rehabilitation facilities for stroke patients, but 
once they are discharged home, there are often no disease management services offered. 
Moreover, there are many Diabetes Education centres focused on nutrition and blood 
glucose control, but these often do not address other vascular risk factors or offer 
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supervised exercise. Finally, recent data suggests that upwards of 10% of these patients 
end up attending two or more disease management programs 19. 
As a result, there is an increasing trend for CR programs to provide service to 
patients with other vascular indications20. However there has been little study of the 
nature of these patients and hence how services may need to be tailored to meet their 
needs, nor has there been ample study on the outcomes achieved in vascular disease 
patients. Thus, the objectives of this stUdy were to compare: (1) CR utilization by clinical 
indication, (2) the sociodemographic and clinical characteristics of vascular disease 
patients who participate in CR versus those who do not, and (3) change in vascular risk 
factors, functional capacity, psychosocial well-being and health behaviors from pre to 
post-program in CD versus vascular disease patients who participated in CR. 
Methods 
Design and Procedure 
This research was observational, and prospective in design. Patients were assessed 
pre and post-CR program at each of 4 participating sites in the Greater Toronto Area of 
Ontario, Canada. Of these programs, 2 were academic. 
At the first CR visit, all patients were approached to solicit informed consent. All 
patients completed an intake assessment as part of standard care. This included risk factor 
assessment, an exercise stress test, and blood work. The exercise stress tests were 
primarily undertaken on a treadmill (n=39; 97.5%), using a Bruce protocol (n=80; 
97.6%)21,22. 
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Consenting patients were emailed and asked to complete a survey administrated 
online using "SurveyMonkey"23 • The survey assessed sociodemographic characteristics, 
functional capacity, exercise behavior, nutrition, medication adherence, smoking status, 
depressive symptoms, and quality of life. 
The assessment protocol was repeated 6 months from the patient's CR intake 
date, which corresponded with the end of the CR programs. For patients who completed 
the program, this entailed a discharge assessment as part of standard care, similar to the 
intake assessment outlined above. Again, some of this available clinical data was 
extracted. A second self-report online survey was emailed to all participants. It assessed 
the same elements as above, in addition to participation in CR, and barriers to CR 
participation. To optimize response rate, a repeat email was sent to non-responders, and 
then they were phoned. 
Participants 
New patients were approached at first CR contact at the four programs described 
above. One of the programs served cardiac and stroke patients; two were integrated 
vascular programs where cardiac, stroke, diabetes, and renal patients were solicited to 
participate. 
The inclusion criterion was that the patient was still deemed eligible to complete 
CR following their intake assessment. The exclusion criterion was lack of English-
language proficiency. 
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Measures 
To describe the sociodemographic characteristics of the participants, the 
following were assessed in the pre-CR survey: ethnic background, marital status, 
education level, and work status. Patient clinical characteristics extracted from CR charts 
included age, sex, referral and intake dates (to compute wait times), referral indication 
and diagnoses (to categorize patients as CD or vascular disease), risk factors, and 
exercise stress test results. Patients were also asked to self-report their smoking status. 
There were seven psychometrically-validated scales administered in both surveys. 
These scales were chosen based on their reliability and validity when adminis~ered in 
cardiac samples. First, the Duke Activity Status Index (DASI)24, is a 12-item self-report 
scale where patients are asked about activities of daily living. Higher scores denote 
greater functional capacity. 
The Godin Leisure-Time Exercise Questionnaire (GLTEQ)25 is a brief and 
reliable instrument to assess usual physical activity during a one-week period. 
Frequencies of strenuous, moderate, and light-intensity activities are assessed. Higher 
scores indicate greater exercise. 
The Health Promoting Lifestyle Profile II (HPLP 11)26 Nutrition Subscale contains 
6 statements that assess daily personal nutrition habits. Response options range from 1 to 
4 (never to routinely), indicating the frequency that particular nutrition behavior is 
practiced. A mean was computed, with higher scores representing a healthier diet. 
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The Morisky Medication Adherence Scale (MMAS)27 is a 4-item questionnaire. 
Response options are "Yes" I agree with the statement or "No" I do not. Responses are 
summed, and a total score of less than 4 indicates non-adherence. 
The Patient Health Questionnaire (PHQ-8)28 is a reliable and validated depressive 
symptom screening scale that inquires about the frequency of depressed mood in the last 
2 weeks. Each item is scored on a Likert-type scale from 0 to 3 (Not at all to nearly every 
day). A total score was computed by summing responses, with higher scores indicating 
more severe depressive symptoms. Item 9 which assesses suicidal ideation, was excluded 
for ethical reasons. Total scores between 1-4 indicate 'Minimal depression', 5-9 'Mild 
depression', 10-14 'Moderate depression', 15-19 'Moderately severe depression', and 
20-27 'Severe depression'. A cut-off of~ 10 was applied to denote elevated depressive 
symptoms29• 
The EuroQol (EQ-5D)3°'31 is a reliable and validated 5-item quality of life scale. 
Respondents indicate their health status by choosing one of three response options (no 
problem to extreme problem) in each of 5 life dimensions. Responses are combined to 
compute a unique health state. The EQ also has a visual analogue scale item30'31 where 
the respondents' were asked to self-rate their health on a vertical scale where the 
endpoints are labeled 'Worst imaginable health state' (0) and 'Best imaginable health 
state' (100). 
Furthermore, one psychometrically-validated scale was administrated only in the 
post-test survey. The Cardiac Rehabilitation Barriers Scale (CRBS)32 is a 19-item scale 
which assesses multi-level barriers to CR applicable to enrollees and non-enrollees. 
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Responses were reported on a Likert scale from I (Strongly disagree) through to 5 
(Strongly Agree). A mean score was computed to reflect total CR barriers, wi)th greater 
scores reflecting greater perceived barriers. 
Finally, investigator-generated items with forced-choice response options were 
included in the post-test survey to assess self-reported CR utilization. Specifically, CR 
enrolment (i.e., whether they completed an intake assessment; y/n), whether they 
participated in the program [y/n ], program adherence (i.e., the percentage of prescribed 
CR sessions they attended), and whether they completed the program (graduated; y/n) 
were assessed. 
Statistical Analyses 
First, a frequency examination of clinical referral indication for CR was 
performed. This formed the basis for the independent variable of CD versus vascular 
disease created. The sociodemographic and clinical characteristics of participants were 
explored. These were compared by CR indication (i.e., CD vs. vascular disease), by 
performing Mann-Whitney U tests or chi-square analyses as applicable. 
To test the first objective, chi-squared tests were performed to determine if there 
were significant differences between type of CR program attended and CR completion by 
CR indication. As well, Mann-Whitney U tests were performed to determine if there were 
significant differences between CR wait times, degree of CR participation and CR 
barriers by clinical indication. 
To test the second objective, vascular disease patients were selected, and the pre-
CR sociodemographic and clinical characteristics of those who participated in CR versus 
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those who did not were compared using chi-square or Mann-Whitney U tests, as 
appropriate. To test the third objective, a descriptive analysis of the outcomes under study 
was performed at pre and post-test, by clinical indication, among those who participated 
in CR. Mann-Whitney U and Wilcoxon signed rank tests were performed to ascertain 
whether there were significant changes from pre to post-test in the risk factors, functional 
outcomes, psychosocial indicators and health behavior variables, as appropriate. Given 
the large number of comparisons performed, a conservative p-value ofp<.01 was applied 
to mitigate inflated error rates. 
Results 
Respondent Characteristics 
A diagram of patient accrual and retention is shown in Figure 1. As shown, 
clinical data from the CR intake assessment was not available for 8 (2.8%) patients, as 
they did not enroll following their initial visit. For 82 (29.0%) patients there was no 
discharge assessment undertaken, due primarily to dropout (n=70, 90.9%), and also that 
some patients failed to remit blood work and attend their post-program stress test (n=6 l, 
85.9%). Thus, there were 156 (79.2%) discharge assessments available in the charts for 
CD and 70 (82.4%) for vascular disease patients (p=0.50). 
Of these patients, 85 (30.l %) were categorized as vascular disease. As shown in 
Table 1, other CR indications were most-commonly stroke and diabetes. Overall, 204 
(73.4%) patients were considered to have monovascular disease (i.e., only one of cardiac, 
stroke or diabetes). 
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The sociodemographic characteristics of the sample are also shown in Table 1. 
CD patients were significantly more likely to be male than vascular disease patients. The 
pre-CR clinical characteristics of participants are displayed in Table 2. CD patients had 
significantly lower body mass index and glycated hemoglobin, as well as significantly 
greater functional capacity than vascular disease patients. They were also significantly 
more adherent to their medications than vascular disease patients. No other differences 
were observed. 
CR Utilization 
As per the first objective, CR utilization is shown in Table 3. Overall, 180 
(72.3%) patients self-reported participating in the program after their initial visit, and 
this, as well as the degree of program participation among those enrolled, did not vary by 
indication. However, CD patients reported being significantly more likely to complete 
CR than their vascular disease counterparts. CR barriers did not differ by referral 
indication. 
As per the second objective, there were no significant differences in the pre-CR 
sociodemographic, clinical or psychosocial characteristics of vascular disease patients 
who participated in CR versus those that did not (Table 4). However, vascular disease 
participants who attended CR engaged in significantly greater physical activity pre-
program than those who did not attend. 
Outcomes 
Table 2 displays risk factors, functional status, psychosocial well-being, and 
health behaviors at pre- and post-test for both CD and vascular disease patients, and by 
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CR participation. To test objective 3, those who self-reported participation in CR were 
selected, and Wilcoxon Signed Rank tests were performed to investigate challges from 
pre to post-test assessment by CR indication (see t). Among CD patients, significant 
increases in functional capacity, exercise behavior and nutrition were observed. Among 
vascular disease patients, no significant differences were observed at the p<.01 level, 
however there were trends towards reductions in depressive symptoms (p=.05), and 
increases in physical activity (p=.09). 
Discussion 
Through this practical, multi-site study, the applicability of CR has been shown to 
be beneficial to patients with stroke and diabetes. Primary observations include the 
different presentation of vascular disease patients, the low rates of program completion 
(which are even lower among the vascular disease patients), but general trends towards 
improvements in psychological well-being and health behaviors. 
Vascular disease patients may have somewhat different needs from CR programs, 
based on some notable differences in their clinical presentation at program entry. 
Vascular disease patients present with higher body mass index, greater HbA 1 c, lower 
functional capacity and lower medication adherence than traditional CR patients. This 
suggests that CR programs may need to consider whether their program equipment can 
sustain the greater weight of patients, and their blood pressure cuffs have sufficient 
circumference. Integration of the recent American Association of Cardiovascular and 
Pulmonary Rehabilitation guidelines for diabetes in CR programs would also be 
needed33• Moreover, given their lower functional capacity, choice of intake exercise 
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protocol and modality should be tailored accordingly. Finally, given the potentially 
higher number of medications required for patients with polyvascular disease, medication 
review and education would be particularly central, as would be integrating proven 
interventions to promote medication adherence34• Program access to a pharmacist would 
be ideal as patient disease complexity increases, so do the potential for drug interaction 
and side effects and therefore poly-pharmacy will play a crucial role I patient 
management. 
The findings of the present study suggest that CD patients are significantly more 
likely to complete CR in comparison to their vascular disease counterparts. This is likely 
not explained by the barriers which were assessed, as no differences by indication were 
observed. There was only one significant difference in the characteristics of vascular 
disease patients who participated in the program after the initial visit, versus those who 
did not. This difference in history of exercise is comparable to the differences observed in 
cardiac samples35• Perhaps then, the differences in utilization are somewhat explained by 
the different characteristics upon presentation (as outlined above), and hence different 
needs of these patients. It is likely that proven strategies to promote adherence in CR, 
such as action (when, where, and how to act) and coping (how to deal with anticipated 
barriers) planning36, could provide a needed boost to program adherence and completion 
rates for all participants, regardless of their indication. 
Research and policy implications 
The implications of the current study are limited by the nature of the study design. 
Randomized controlled trials are needed in vascular disease patients, particularly other 
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than stroke, to determine whether they indeed similarly benefit from CR, in terms of 
some of the proximate outcomes assessed herein, but also in terms of effects on 
morbidity and mortality. Indeed, a search of clinicaltrials.gov reveals that many such 
trials are currently underway, and some of which include cost analyses. 
Limitations 
First, the sample is one of convenience, such that CR program staff were trained 
to approach all new patients to solicit study participation. They did not record number 
approached, and therefore the response rate is unknown. Consequently, the 
generalizability of the findings is not known. Second, results are also potentially biased 
due to selection, such that findings may only be applicable to patients who are referred to 
CR. It is known that only approximately 30% of cardiac patients are referred to CR in 
Ontario37, and this number would likely be much lower among vascular disease patients. 
Moreover, patients who enroll are often not those in greatest need of these services, for 
example higher functioning, English-speaking male patients of higher socioeconomic 
status patients are over-represented in CR20• Third, due to the low rates of CR 
completion, post-test clinical parameters were not available for most participants, which 
raises the potential of bias. Retention in the study to complete the post-test survey was 
fair however. Fourth, all vascular diseases being considered in this study may not have 
been recorded in CR charts. This may have led to some misclassification of CD and 
vascular disease patients which could contaminate findings. Chart extractors for the study 
were provided training to mitigate this threat, as well as a coding guide. Duplicate audit 
of some charts was undertaken to determine how much of a threat misclassification could 
25 
be to the findings, and was deemed to be low. Furthermore, patients with non-cardiac 
primary indications may ultimately have had underlying but undocumented cardiac 
disease, and therefore the categorization of cardiac versus other or polyvascu1ar may be 
artificial or imprecise. Fifth, many of the outcomes are self-reported, which raises the 
possibility of expectation bias and socially-desirable responding. However, the 
measurement protocol is the same for the CD and vascular disease participants, so this 
should not have negatively impacted the between-group comparisons. Moreover, exercise 
stress test results were extracted, which is an objective and valid measure. Sixth, this is an 
observational study, and therefore causality cannot be inferred. Certainly, the results from 
this study suggest a randomized controlled trial may be warranted. Finally, 
generalizability is limited to healthcare systems where outpatient vascular rehabilitation 
services are offered at no cost to referred patients. 
In conclusion, this practical examination of integrated chronic disease 
management provides some supporting evidence for the benefits of CR for other vascular 
. patients, and accommodations in CR is warrant for these unique patient populations. 
While rates of program completion were low, results suggested vascular disease patients 
may achi~ve reductions in depressive symptoms and improvements in exercise behaviour 
following participation. In order to provide patient-centered, high-quality and cost-
effective care for the growing number of people with vascular diseases globally, proven 
chronic disease management models such as CR could play an important role in ensuring 
an integrated outpatient journey. 
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Figure 1: Study Flow Diagram 
Patients recruited from the cardiovascular 
rehabilitation (CR) program upon initial 
contact: 
N=282 consented 
/ 
Patients completed a 
pre-CR survey 
n=237 (84.0%) 
Cardiac, n = 170 (86.3%) 
Vascular, n = 67 (78.8%) I 
/ 
Patients completed a 
post-test survey 
n=201 (71.3%) 
Cardiac, n = 146 (85.9%) 
Vascular, n = 55 (82.1%) 
l Cardiac, n = 197 (69.9%) Vascular, n = 85 (30.1%) 
Clinical data from CR 
intake assessment was 
extracted from charts, ' 
n=274 (97.2%) "' 
\ Cardiac, n = 190 (96.4%) Vascular, n = 84 (98.8%) 
Clinical data from CR 
discharge assessment 
was extracted from 
charts, n=226 (80 .1 % ) ' 
...._______, "' 
Cardiac, n = 156 (82.1 % ) 
Vascular, n = 70 (83.3%) 
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Table 1: Sociodemographic and Referral Indications of Cardiac versus Other or Polyvascular 
Disease Patients Pre-Program 
Characteristic CD (n=l96, 72.3%) VD (n=83, 29.7%) Total (N=279) 
Sociodemographic 
Aget (mean years± SD) 64.98 ± 10.68 66.58 ± 10.11 65.44 ± 10.50 
Sext (% Male) 143 (73.7%) 47 (59.5%) 190 (69.6%) * 
Ethnicity (% North American) 67 (41.9%) 24 (38.1%) 91 (40.8%) 
Marital Status (% married) 122 (76.7%) 49 (76.6%) 171 (76.7%) 
Education (% Completed less 89 (52.4%) 33 (50.0%) 122 (51.7%) 
than college I university) 
Work status (% currently 82 (48.2%) 36 (54.5%) 118 (50.0%) 
retired) 
CR Referral 
Cardi act 194 (99.0%) 62 (73.8%) 256 (92.1%)*** 
PCI 83 (43.5%) 25 (29.8%) 108 (39.3%)* 
CAD 76 (39.8%) 23 (27.4%) 99 (36.0%)* 
CABG 58 (30.4%) 18 (21.4%) 76 (27.6%) 
MI 59 (30.9%) 15 (17.9%) 74 (26.9%)* 
Arrhythmia 20 (10.5%) 9 (10.7%) 29 (10.5%) 
HF 11 (5.8%) 5 (6.0%) 16 (5.8%) 
Congenital 4 (2.1%) 1 (1.2%) 5 (1.8%) 
Stroket 22 (26.2%) 22 (8.0%)*** 
Diabetest 16 (19.0%) 16 (5.8%)*** 
PVD 3 (3.6%) 3 (1.1%)** 
Othert (e.g., Vascular Risk 
26 (31.0%) 26 (9.5%)*** 
Factors, Renal) 
CD, Cardiac Disease; VD, polyVascular Disease; SD, standard deviation; PCI, Percutaneous 
Coronary Intervention; CAD, Coronary Artery Disease; CABG, Coronary Artery Bypass 
Graph; MI, Myocardial Infarction; HF, Heart Failure; PVD, Peripheral Vascular Disease. 
*p<.05, **p<.01, ***p<.001 
tchart report. 
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Ta hie 2: Risk Factors, Functional Status, Psychosocial Well-being, and Health Behaviours at Pre and Post-Test among Cardiac versus Other or Polyvascular Disease Patients by CR 
Enrolment Status 
Dependent Variable Pre-CR Post-CR 
CD VD Total Pre-CR CD (no CR, CD (CR, Total CD VD (no CR, VD (CR, n=53, Total VD Total Post-CR 
(n=l 97, 69.9%) (n=85, 30.1 %) (n=282,100%) n=52, 26. 8%) n=l42, 73.2%) (n=l 94, 70.0%) n=30, 36.1 %) 63.9%) (n=83, 30.0%) (n=277, 100%) 
Risk Factors 
TC(mmoUL) 4.06±1.16 4.18 ± 1.45 4.02 ± 1.20 
-
3.61±0.78 3.61 ± 0.78 
-
3.63 ± 0.70 3.63 ± 0.70 3.61±0.77 
HDL (mmoUL) 1.15 ± 0.32 1.19±0.40 1.15 :I: 0.38 
-
1.16 ± 0.33 1.16 ± 0.33 
-
1.21±0.45 1.21 ± 0.45 1.19 :I: 0.38 
LDL (mmol/L) 2.30 :I: 0.92 2.21±1.16 2.25 :I: 0.94 
-
1.92 ± 0.60 1.92 ± 0.6011 
-
1.83 ± 0.46 1.83 ± 0.46 1.89 :I: 0.58 
Triglycerides 
1.34 ± 0.87 1.63 ± 1.17 1.33 :I: 0.94 1.17±0.53 1.17 ± 0.53 1.30 ± 0.70 1.30 ± 0.70 1.19 :I: 0.58 (mmol/L) - -
TC/HDL Ratio 3.74±1.41 3.71±1.52 3.86:I:1.68 
-
3.25 ± 0.85 3.25 ± 0.8511 
-
3.14 ± 0.89 3.14 ±0.8911 3.18 :I: 0.88 
BMI (kglm2) 28.39 ± 4.43 30.59 ± 6.04 28.79 :I: 4.50* 
-
28.54 ± 4.35 28.54 ± 4.35 
-
29.39 ± 5.32 29.39 ± 5.32 28.67 :I: 4.44 
WC(cm) 101.77 ± 9.93 105.28 ± 13.17 102.16 :I: 10.87 
-
100.16±12.14 100.16 ± 12.14 
-
103.63 ± 13.62 103.63 ± 13.62 101.15 :I: 11.60 
SBP (mmHg) 126.02±18.45 127.49±17.49 126.53::1::18.43 
-
120.31±13.54 120.31±13.5411 
-
120.72 ± 16.90 120.72 ± 16.90 120.47 :I: 14.56 
DBP (mmHg) 74.87 ± 11.23 74.16 ± 10.52 74.86 ± 10.77 
-
69.07 ±9.90 69.07 ± 9.901111 
-
66.15 ± 9.39 66.15 ±9.3911 68.18 :I: 9.86 
HbAlc (%) 5.89 ± 0.49 6.73 ± 1.08 6.26 ± 0.95** 
-
5.86 ± 0.35 5.86 ± 0.35 
-
6.45 ± 0.84 6.45 ± 0.84* 6.11±0.50* 
Functional Capacity 
METs 7.52 ± 3.10 6.30 ± 2.45 7.39 ± 3.06* 
-
9.14 ± 3.08 9.14 ± 3.081111 
-
7.49 ± 2.61 7.49±2.61* 8.84 ± 2.96* 
V02mox 26.32 ± 10.86 22.05 ± 8.59 25.87 ± 10.69* - 32.01±10.77 32.01±10.771111 - 26.20 ± 9.13 26.20 ±9.13* 30.95 ± 10.37* 
DASI§ 39.25 ± 14.47 37.64 ± 14.53 38.44 ± 14.53 42.61±14.29 46.10 ± 14.14tt 45.56 ± 14.121111 34.63 ± 14.89 36.50 ± 15.03 36.45 ± 15.04** 43.43 :I: 15.27** 
Psychosocial Well-Being§ 
Depressive 
3.60 ± 4.20 5.22 ± 5.48 3.45 ± 4.02 4.10 ± 4.69 2.71 ± 3.56 2.97 ± 3.82 6.24 ± 5.32 3.57 ± 4.29 4.44 ± 4.72 3.39 :I: 4.14 Symptoms 
Quality of Life 0.86 ± 0.14 0.86 ± 0.11 0.86 ± 0.13 0.90±0.13: 0.89 ± .014 0.89 ± 0.1411 0.82±0.15 0.85±0.17 0.84±0.16 0.88 ± 0.15* 
Quality of Life 
77.55 ± 14.40 70.25 ± 17.81 75.57 :I: 17.05 76.90 ± 12.19 82.34 ± 13.59 81.14 ± 13.32 73.83 ± 20.50 72.32 ± 18.82 72.91 ± 18.87 80.41±17.38 (visual scale) 
Health Behaviours§ 
Physical activity 18.60 ± 21.02 18.87±21.46 19.08 ± 21.14 27.87 ± 39.86 29.04 ± 28.56t 29.59 ± 30.991111 42.23 ± 63.06 21.67 ± 22.30 28.02 ± 39.27 30.75 ± 33.63 
Nutrition 2.92 ± 0.53 3.05 ± 0.51 3.00 ± 0.54 2.71±0.47 3.15 ± 0.48t 3.05 ± 0.51 3.00 ± 0.43 3.09 ± 0.60 3.07 ± 0.55 3.07 ± 0.51 
Medication 3.68 ± 0.66 3.48 ± 0.77 3.59 ± 0.73 Adherence 3.62 ± 0.70* 3.66 ± 0.59 3.64 ± 0.62 3.65 ± 0.61 3.51±0.77 3.55 ± 0.72 3.60 :I: 0.65 
Smoking 8 (4.8%) I (1.5%) 9 (3.8%) 2 (6.7%) 6 (5.3%) 8 (5.5%) 0 (0%) I (2.7%) I (1.8%) 9 (4.5%) (Current,%) 
CR, Cardiovascular Rehabilitation; CD, Cardiac Disease; VD, Polyvascular Disease; SD, standard deviation; TC, Total Cholesterol; HDL, High Density Lipoprotein; LDL, Low Density 
Lipoprotein; BMI, Body Mass Index; WC, Waist Circumference; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HbA I c, Glycated Haemoglobin; METs, Metabolic Equivalents 
Tasks; V02max, Maximal Oxygen Consumption. 
§assessed via self-report 
*p<.O I, ••p<.00 I for pre-CR CD vs VD, as \.\ell as post CD CR vs no CR and VD CR vs no CR 
llp<.O 1, llllp<.00 I for Wilcoxon Signed ranks test pre vs post-CR CD vs VD Total 
tp<.01, ttp<.001 for Wilcoxon Signed ranks test CD CR, and VD CR pre compared to post-test; 
ip<.O I, Up<.001 for Wilcoxon Signed ranks test CD no CR, and VD no CR pre to post-test 
Table 3: CR Utilization and Barriers among Cardiac versus Other or Polyvascular Disease Patients 
CR Enrolment (%) 
CR Participation (%) 
CR Wait Timest (mean days± 
SD) 
CR Program Modelt (% 
supervised) 
% Sessions Attendedt (mean± 
SD) 
CR Completiont (%) 
Total CR Barriers (mean± SD) 
CD (n=l 73, 69.5%) VD (n=76, 30.5%) Total (N=249) 
141 (97.9%) 48 (96.0%) ]89 (97.4%) 
135 (97.1%) 45 (93.8%) 180 (96.3%) 
38.66 ± 73.30 
133 (85.8%) 
68.82 ± 34.78 
104 (68.9%) 
1.64 ± 0.76 
37.50 ± 32.26 
62 (91.2%) 
61.86 ± 32.61 
37 (54.4%) 
1.75 ± 0.79 
38.31 ± 63.57 
195 (87.4%) 
66.65 ± 34.18 
141 (64.4%)* 
1.67 ± 0.76 
CR, Cardiovascular Rehabilitation; CD, Cardiac Disease; VD, Polyvascular Disease; SD, standard 
deviation;. 
*p<.05, **p<.01, ***p<.001 
tchart report. 
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Table 4. Pre-Test Characteristics of Vascular Disease Patients by CR Participation. 
Characteristic CR (n=51, 63.0%) No CR (n=30, 37.0%) Total (N=81) 
Sociodemographic§ 
Age (mean years± SD) 66.67 ± 10.64 66.53 ± 9.66 66.58 ± 10.11 
Sex(% Male) 32 (65.3%) 14 (48.3%) 46, (59.0%) 
Ethnicity (% North 
19 (47.5%) 4 (18.2%) 23 (37.1%) 
American) 
Marital Status (% 
29 (72.5%) 19 (82.6%) 48 (76.2%) 
married) 
Education(% Completed 
college/university or 22 (53.7%) 10 (43.5%) 32 (50.0%) 
higher) 
Work status (% currently 
22 (53.7%) 13 (56.5%) 35(54.7%) 
retired) 
Risk Factors 
TC (mmol/L) 4.14± 1.45 4.24 ± 1.48 4.18 ± 1.45 
HDL (mmol/L) 1.25 ± 0.43 1.10 ± 0.33 1.19 ± 0.40 
LDL (mmol/L) 2.08 ± 1.04 2.38 ± 1.31 2.21±1.16 
Triglycerides (mmol/L) 1.63 ± 1.26 1.62 ± 1.04 1.63 ± 1.17 
TC/HDL Ratio 3.55 ± 1.59 3.92 ± 1.41 3.71±1.52 
BMI (kg/m2) 29.20 ± 4.78 32.74 ± 7.20 30.59 ± 6.04 
WC (cm) 103.43 ± 11.56 107.97 ± 15.18 105.28 ± 13.17 
SBP (mmHg) 127.84 ± 18.67 127.55 ± 15.47 127.49 ± 17.49 
DBP (mmHg) 73.42 ± 10.88 75.52 ± 10.09 74.16 ± 10.52 
HbAlc (%) 6.61±0.95 6.88 ± 1.24 6.73 ± 1.08 
Functional Capacity 
ME Ts 6.38 ± 2.53 6.13 ± 2.41 6.30± 2.45 
V02max (ml/kg/min) 22.33 ± 8.85 21.46 ± 8.44 22.05 ± 8.59 
DASI§ 39.37 ± 13.87 32.84 ± 14.85 37.64 ± 14.53 
Psychosocial Well-Being§ 
Depressive Symptoms 5.37 ± 5.87 4.96 ± 5.09 5.22 ± 5.48 
Quality of Life 0.86 ± 0.12 0.84± 0.08 0.86± 0.11 
Quality of Life (visual 67.42 ± 20.85 76.83 ± 12.34 70.25 ± 17 .81 
scale) 
Health Behaviours§ 
Physical activity 22.90 ± 23.01 12.10 ± 18.05 18.87 ± 21.46* 
Nutrition 3.01±0.55 3.11±0.45 3.05 ± 0.51 
Medication Adherence 3.54 ± 0.81 3.38 ± 0.71 3.48 ± 0.77 
Smoking (Current,%) 1 (2.4%) 0 (0.0%) 1 (1.6%) 
CR, Cardiovascular Rehabilitation; VD, Polyvascular Disease; SD, standard deviation; TC, Total Cholesterol; HDL, 
High Density Lipoprotein; LDL, Low Density Lipoprotein; BMI, Body Mass Index; WC, Waist Circumference; SBP, 
Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HbAlc, Glycated Haemoglobin; METs, Metabolic 
Equivalents Tasks; V02max, Maximal Oxygen Consumption. 
§assessed via self-report 
*p<.05. 
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Extended Results 
Other Objectives 
As per the first objective of the thesis, to test whether the relationships observed 
sustained adjustment, general linear models were computed for the outcomes for which a 
difference by time was observed in the manuscript (including the trends). A propensity 
score was computed to adjust for differences in characteristics of CD and vascular 
disease participants, except for those which were not assessed in all participants (i.e., 
glycated hemoglobin not applicable to participants without diabetes). The models were 
adjusted for degree of CR participation, propensity score and pre-CR value. Observed 
power for the full models ranged from 0.72-1.00, but the power for degree of CR 
participation (ranging from 0.05-0.16) and for indication (ranging from 0.06-0.20 except 
for the activity status model which was 0.76) was very low in all models. 
As shown in Table 5, all models were significant. With regard to activity status, 
higher scores at post-test were significantly associated with higher scores at pre-test, and 
CD indication. This again suggests that vascular disease patients are more complex, and 
may have unique needs. With regard to depressive symptoms, physical activity and 
nutrition, scores were significantly associated with pre-test symptoms only. It cannot be 
determined whether indication or CR participation are significantly related to these 
outcomes due to insufficient power. Further research is needed. 
As per the second objective of the thesis, self-reported confidence with exercise43 
(see Appendix P) and perception of chronic disease care44 (see Appendix Q) was 
compared among CD versus other or vascular disease patients post-CR (see Table 6). 
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Mann-Whitney U-tests were performed, and no significant differences were observed in 
either instance (p=0.32 and p=0.93, respectively). 
In summary, overall many of the hypotheses proposed were not supported. With 
regard to objective one of the thesis, significant improvements in all outcomes were not 
observed among CR participants. This could be explained by lack of power, or 
insufficient intensity of the CR programs. With regard to the second objective, we 
hypothesized that no differences in CR utilization and other similar parameters would be 
observed by indication. This was mostly supported, except CD patients were significantly 
more likely to complete CR than vascular disease patients. This could potentially be 
explained by their greater complexity, and that the programs are designed with the needs 
of CD patients. 
Missing Data 
Some data were missing for several reasons. First, because research participation 
is voluntary, patients always had the option not to complete items that made them feel 
uncomfortable. For example, activity status (question 12) was notably missing for 
11(3.8%) participants. Second, the self-report surveys have gone through several 
amendments, and therefore all variables were not administered to all patients. For 
example, the quality of life and depressive moods were not assessed in all patients until 6 
months after the program evaluation began. Finally, clinical chart reporting varied across 
the CR programs, and therefore clinical characteristics were sometimes missing. Fourth, 
some patients were lost-to-follow-up (i.e., nonresponse). Some patients did not complete 
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the follow-up survey (n=81, 28. 7% ). Patients who did not complete the CR program did 
not have a clinical discharge assessment (n=56, 19 .9% ). 
To minimize missing data, repeated contacts to patients was built into the study 
protocol. For the purposes of this thesis, missing clinical data was not imputed. We 
attempted to undertake robust non-parametric statistical approaches. Listwise deletion 
was used, and therefore in some instances the sample being analyzed was smaller than 
the total sample size. 
Statistical Assumptions 
Non-parametric test were applied throughout the thesis, as homogeneity of 
variance between the CD and vascular disease patients could not be assumed due to 
unequal sample sizes. Kolmogorov-Smimov statistic was calculated to determine if the 
sample were normally distributed, and activity status (Dn=0.125, p<0.001), physical 
activity (Dn=0.187, p<0.001), nutrition (Dn=0.0.75, p=0.002) and depressive moods 
(Dn=0.191, p<0.001) were all not normally distributed. 
Finally, Cronbach's alpha was calculated to test the internal reliability of the 
psychometrically-validated scales by CR indication and time point (Table 7). As shown, 
Cronbach's alpha was considered acceptable for all scales except for the nutrition 
subscale. This could be due to t4e small number of items in the subscale (i.e., 6). Thus, 
caution should be warranted in drawing conclusions in relation to the nutrition behavior 
of participants in the study. 
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Extended Discussion 
It is reported that 10% of CD patients in Ontario are accessing multiple chronic 
disease management programs45• There also appears to be a lack of communication 
between CR and various chronic disease management programs patients are receiving 
care45 • Moreover, 62.2% of CR programs across Ontario already offer services to patients 
without CD as a primary referral indication31 • There is clearly a need for greater 'cross-
talk" between ambulatory programs in the province. 
The Ontario Vascular Health Coalition formed in 2010, through collaboration of 
the Heart and Stroke Foundation of Ontario, the Ontario Stroke Network and the Cardiac 
Care Network of Ontario. They developed a Blueprint for "an integrated, patient-
centered, accessible continuum of high quality vascular health services and resources that 
facilitates and fosters improved vascular health, reduced incidence of vascular disease 
and reduced consequences of vascular-related diseases for all Ontarians" 
(http://www.opha.on.ca/Integrated%20Vascular%20Health%20Blueprint%20for%200nt 
ario August%202012.pdf). Dr. Sherry Grace serves as chair of their knowledge 
management work group for the Coalition, and will present these preliminary findings to 
the steering committee to inform the development of integrated chronic disease 
management programs in the province. 
In conclusion, this thesis has provided information on the profile of vascular 
disease patients who are being treated in CR programs. While definitive conclusions 
cannot be drawn from this observational study, results suggest that CD patients are 
achieving some of the benefits of CR, and vascular disease patients may as well. 
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Table 5: General Linear Models Assessing Differences Between Cardiac vs Polyvascular 
Disease Patient Outcomes at Post-Test* 
Outcome F p l'\p 2 
Functional Status 
DASI-Model 48.889 <0.001 0.640 
Propensity Score 7.667 0.007 
Indication 7.157 0.009 
Pre-test DASI 101.177 <0.001 
Degree of CR Participation 0.377 0.540 
Psychosocial Well-Being 
Depressive Symptoms-Model 26.987 <0.001 0.422 
Propensity Score 0.359 0.550 
Indication 1.254 0.266 
Pre-test PHQ 89.406 <0.001 
Degree of CR Participation 0.831 0.363 
Health Behaviors 
Physical Activity-Mode/ 2.615 0.038 0.073 
Propensity Score 0.412 0.552 
Indication 0.502 0.480 
Pre-test Godin 7.497 0.007 
Degree of CR Participation 0.000 0.994 
Nutrition-Model 14.061 <0.001 0.284 
Propensity Score 1.735 0.190 
Indication 0.086 0.769 
Pre-test HPLP-11 44.818 <0.001 
Degree of CR Participation 0.953 0.331 
DASI, Duke Activity Status Index; CR, Cardiovascular Rehabilitation; PHQ, Patient Health 
Questionnaire; HPLP, Health Promoting Lifestyle Profile II. 
*models adjust for degree of CR participation, sex, as well as pre-CR BMI, V02 max, and 
depressive symptoms through a propensity score. 
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Table 6: Self-Reported Confidence with Exercise and Perception of Chronic Disease Care among 
Cardiac versus Other or Polyvascular Disease Patients 
CESEI (mean± SD) 
PACIC (mean± SD) 
CD (n=127, 74.3%) 
3.90 ± 0.87 
2.70±1.10 
VD (n=44, 25.7%) 
3.73 ± 0.63 
2.76±1.28 
Total (N=171) 
3.90 ± 0.83 
2.75±1.15 
CD, Cardiac Disease; VD, Polyvascular Disease; SD, standard deviation; CESEI, Cardiac Exercise Self-
Efficacy Instrument; PACIC, Patient Assessment of Chronic Illness Care. 
*p<.05, **p<.01, ***p<.001 
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Table 7: Internal Reliability of Psychometrically-Validated Scales Scored on Likert Scales 
(Cronbach's a), by sample and time 
Scale Pre-test CD Post-test CD Pre-test VD Post-test VD 
PHQ-8 0.862 0.852 0.865 0.836 
HPLP-11 Nutrition Subscale 0.637 0.614 0.553 0.676 
CESEI* 0.919 0.905 
PACIC* 0.957 0.966 
CRBS* 0.912 0.914 
CD, Cardiac Disease; VD, Polyvascular Disease; PHQ-8, Patient Health Questionnaire-8; HPLP, Health 
Promoting Lifestyle Profile II; CESEI, Cardiac Exercise Self-Efficacy Instrument; PACIC, Patient 
Assessment of Chronic Illness Care; CRBS, Cardiac Rehabilitation Barriers Scale. 
*Only administered at post-test. 
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Appendices 
Appendix A: Study Design 
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l 
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Appendix B: Informed Consent Form (York University) 
YORK 
I! 
llMU~'t·s:;tJ.ti; 
U-l\'l~'!ft~ITY 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
Study Name:. CantiovaScnlar Rftabilitation - CUoiaiC Dise&W Maugemmt Pro;ram E;va!Utioa 
aad Cost-mectiveltess Aulysis 
Rnrudien: 
Toman KoWaLBA (lrfScStitdent) 
Midielle Bedard· and .. Cassanm· Comm (MFSc Students) . . . . . 
Yori: • Uninrsity ad UllivHsity .·.llejlth 
NetW0rk 
York Central ·Hospital, DiStrict Sbi>b 
Ceatre 
YerkU. 
Yori.: Uliivenity 
Purpose Of d.ie Rm.rdi: You are being meet to take part iii a zeseaidi study. Please reac}W.this 
explmation abouttbe study 'and its~ and·~ before you decide if you would ~e to take~)mt 
Ym should take u much time as you need to DJake your decisioD. You should ask the slDdy sijlrto 
aplain. anythDig. itJat .you ··do. not uodentand and make· sore that· all of yam questiaos have 1F 
amwered before signing this Consent fmm. Before you .make your~ feel he to 1Dlk aboutthis 
~with anyone you vrisJL• Participation in this study is voluntuy-
Yau have already agreed to participate in the Y cxk. University Cantiovucular Rehabilitation (CR) 
Program. Jn this·retea:rch study, we WOWd like 1D include your iofmmation collected in 1liis ~·for 
resean:h purposes. We would like to use this infonmtiou to 1eam how We can better meet 1he<.nee<Js of 
our clients and to improve the services we provide. We would like to better undel'Stmd how· Jmn-
quality of life. heart risk ·~ knowledge. and health behaviors chmge following~· in 
CR. We are also :interested in studying the cost-drectiveoess of file services we provide to you. 
What You \Vill Be Asked to .Do in the. Resevd: M part of am- pmgnm. you will be -~ to 
CDmplete 4 smveys online: one at the beginning of file caniiovasc:n1ar rehab pmgnm. one. 6·.~ 12 
months ·and 24 ~ later. The surveys include questions about your exeirise· and m11Iition habits, 
memcatian adherence, quality of life. and mood These questiam .help us UDdemana hoW)'Mi'.· are 
managingyomh2altb condition. We also plan to develop a survey 5 years from now. Your ~on 
of all surveys is voluntuy. You can provide your email address at the end of this fimn to Reei\~ an 
email link to 1he survey. 
VR. Program Ewl: YU ICF Vl; June 13. 2012 Pagelof3 
48 
If ymi consent·to participate in this study, your smvey responses would be.used.for;reseucli:~~ 
We would also like to extract clinical infmmation from your dwts (e~~ disease Jii.Uory~ o~ 1health 
problems; risk ~ exeicise. stress test ~ dm1esterol ~·your ~): FijiSlly, we 
would a]so Jike ~ penn1s.qon tolink your infmmation ga11Bed fmm:this ~ "'1$ a ~viDcial 
da1abase to determme.yombealth :care 11se and health mm:omes over time.. 'Ibis wQu1d not'reqiiire any 
papeIWmk on your behalf · 
Pote.nhl BenditS anti Ri$b: Yoo.may or may not m:avemy direct ,benefit rrnm:beingm.tbis stmty. 
Inhmrtion lemDedfmin this study may help o1hecpeople with }'Mii condition in~ future. 
'fhere ~ lK> adtlitim,i~l ~ tD yoo if you take part in.this ,lbldy. Being in this· study may make ymi 
reet 1IDCOlllfortab~ Youmayretme to answer ~.if.dieie is anydi$c;omfint 
As a gt9eal~ email may not always be.asecure method of oomnnmication F~ ·~ .stmty, 
email is;~:uSecl &geoeral tAmmn11iratimt· . . . .· ·•·• .. ·. Ollly;; and will not be nsetMo ~~vi.de ~~'--;,;~~l:•=~~*"'•'•·~ 
:~t#t?e~~~~==:~4cm;: 
IDBY~~ JJ8ture:~r~ongoingre1atiM'•hip youiu.aY ~w.ifbtbe ~:o.r:~~ 
na• ~~~relatinDsbipmlliYmk]Jnil1mity mm~,, or in 1he fUtme. · · · 
WrthclraWalhiothe·Stady:···You<<:aiistopparticipatinginthestndyatany~fmmy~if 
you so decide. Your decision to stop puticipating.Clr to remseto ansm particular:~~~Will not 
aft'ectynor reiatiaoship with 1he.researcbem; Yml Uniwrsity> or any.other group ~{~nth this 
p-oject..Jn the evm.t.you.''WitbdraW from the stwly, allusociated data collected Will be;iJmiiediately destroyed ~~le. . . . 
Confiden1Wity<If JOii agree tD join this study> the study. doctor and ·hisJher study 'fmm lril]; look at 
joor peBcmal health lnfmmatian aDd collect only tlle infmmatiOn they need fm the study~. Peniooal 
health iofmmation is my infmmitinnthat oould be used to identify you and includes: yum: 
·~ 
• emailaddress 
• address, 
• OIIlP~. new or existing medical reconlit, that inclndes types. dates and results• of:medical 
tests orprocedures. ··· 
The infonnalion. that. is collected for the study will be kept in a JOcked and. seaie area. by '16e study 
doctor fur 10 :ye&IS. Only the study team QT 1he people OI groups listed below will be:·ailowed'•tQ look at 
Joor reconk. . . 
Representatives of1he Ymk Univmity's E1hics Review~. may look at the study reconk and at 
your peBcmal health infmmation to· check 1hat the iofmmation collected fur the study is comrl and to 
make sm:e the study fnllowed proper Jaws and guidelines. 
We are collaborating with some other programs in 1he ~ to stndy. how self~gement 
education varies in diff'ereot pmgmns.. 'I'herefore, puts of the iofonnation you provide· in youI; ,mrvey 
may be securely and anonymously shared with 1he research. investigaton from,fbis ~ stwfy .. 
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Please note thahmy ·iDfm:IDatiml that. JOU provide for -this stndy in 1he. olilioe smvey .. :even. th.,>1.@rde-
ideotifiecL when tn.usftned to 1heU.S7 is subject to U,S. laws, and in particular, to tbe.U.S. ~'Act 
TheUSPatriOtActallaws11xtborities.aa:ess.tothereoordsofstudyputicipanlsin1beevem~of:a®ting 
by autbarities~ 
All infi>mlafum cdllected dming.this study. iDc1uding your personal beal1h .infmmation. v.411 ~·kept 
amfideotial and will mt be shaled 'Wifu ~outside the study uoless required by iaw~ YOll"~llnot 
be namedin'any~pm>Ji.catioDS; orpresenDtiom that.may emue fiomthis study. 
If you.decide to leave the study, 1Jie inf0111•alimtabollt}'outhat ~ collected be.fure youkft 1M•:study 
wilh1ill be uSetL ·NO Del1i iJJfnrIDationwillbe ooUeC:tecl wiftwlltjom permluioo 
' . ~;Abut;tje~?'IfJOll~Vl!.~--abouttbe-~·in_geueraI·or:;t~'J.10UI'ro1e intbeSbld:y~ pJeae ~Jreeto.conblct·tbe stu4Y•a>Ori:timrtm,. Tomasz·ICowal,, aumlis ·' ··.. ca•or 
~-~-~-•. ~_._'._~·-_l_i~_-_ •. ~_n_~-·~.:_;_~_u_._:_._._._~_._._·_:~-~-~~-~-~-:_·_ .. .:.:.~ .• _:_•_•_ -~---··;u_:_~.;_'.~-·~-~~-·-.n_·_R.·-~-·-~-~-«-~.:~_~_:_~~-~--•--~-·~-·-~-·-~--~-~M_§~ __ :_~_ ---~--.--•~-~-:.,_·_:_D.:_:_._:_j·~-.'.·'·-·:·;···:_._._.· ~· 
omce OfReSeaidJ. Etbic:S;'S1l~~ Ydlt R.eseazcli Tawer, Ymt UniVeRity (~·41,&::g 
oie.m;iilOD!(iJ~~-· ..... '' .. . . .. ' '. . . . . . . . . ...... . 
Print Study Participant's Full Name Date 
Date 
I I I I I I I I I I I I I I I I I I I I I 1 · I I I I I I I 
VR.ProgmmEvat YUICFVl;June 13,2012 Page3of3 
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Appendix C: Intake Case Report Form 
StudylD#: _____ _ 
1. Age IJIS I 
.2. Sex · C Male D Female 
3. Date Refmal Rec:ei.ved 
dd mmm yyyy 
mmm yyyy 
dd ·mmm yyyy 
6. · · RaeUaI lndica~ Cchd amhatapply> DCantiac . 
llPci' ... 
C.~~and/arV~~ 
·g~~~·(C!.W, 
CtliF 
a~··, 
a·. AfrhYtbmi3; 
0,S~!TIA. 0 'Diatietes ' '· · 
DRenal 
DPVD 
D ArlhritiS clime []'•Other. pleaae speary ____ _ 
1. Risk FactoU · 
Yes No Factor 
Type 
0 ti Diabetes Hb.Ak"J. Date assessed 
BMl(k~) 
0 D Obesity (BMI:»30) Waist circ (cm} Date'a.ssessed 
Details 
IJ T:ypeI I IJType' 
I 
dd mmm I yyyy 
I 
dd 1D1DID I .MY: 
Blood Pressure (BP) I 
0 D Hyperten.tion systolic. I ~DliA· Date assessed I 
dd mmm I· vrnit 
To1al ChDlestmil 
IIDL 
0 D Dyslipidemia IDL Triglycerides 
Date assessed I 
dd mmm I Y'i'i'1 
CR.-CDMProgram.Evaluation CRF. Vemon2. Nowmber 97 2011 Page2of4 
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dd mmm yyyy 
9. Waist ciR:umCermce cm 
10. Int.ake Exercise Stress Test 
Peak.METS 
PmV02 
· u .. CommeDts re: GXT .;..... symptom..fuoited? 
·12~ Cuomt~ Ccliec:k anth3t a}JP]j): 
0 ••• ACE'lnbibifun ff Ant.i-pbrtelets 
o Anti-coaguJams . n BebM>Jockers 
n ASA 0 Digoxin 
0 . Ca2+ antagonists 0 NJ.bateS (not PRN) 
0 · Statm 0 ARBs 
0 IL.-.fibn.te 0 .·~· 
0 ll. "."" nicotinic acid D C.nnmadin 
0 IL-resin drugs 0 Heparin 
0 . DiuretiCs 0 HR.I 
0 Clopidogrel or 0 Insulin 
ticlapidine 0 Oralhypoglycemic 
o Other anti-platelet n Anti-inflammatory 
0 Nicotine Rq>Iacement D· Other ____ _ 
0 Anti-mhytbmic 
l3. FamilyPhysici.an _________ _ 
CR-CDM Program EvaJnation CRF. Venion 2. November 9~ 2011 Pagelof4 
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!;:· ~·--. _, - ........ -- ··~ - '5~.:~~:~~:;:·~~~~~;-~_;)~:-f-·-~~ . 
L~~ _ ~ _ :~~ -~~~~J~~,-~~~~~,~·-;~ -~~~;v~l5;_ ~-~--~~'~'~: ~-;--~ ~ 
StudyID#t ____ _ 
1. Patient's Fim Name: 
3. ··PtefeRed·~ 
Cl Mt 
CJ.~ 
CJMf, 
Cl DI. 
4, .. Patiait'sTe1epwiie~ 
I I I I I I I I I l I 
~cacle) 
5 .. ·palielJl•s AddRsS: 
Street. Address I 
City I 
Pmvim=e ION 1:1 I 
7, A1temate Contact Illfmmation (if willing): 
8. OlllP number: 
--------
CR.-CDMProgwnEvaluation CRF. Version2. Nowmber9, 2011 Page4;of4 
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Appendix D: Discharge Case Report Form 
.sfudj ID#: --
1.. Piograo1 ~utilized Cchec.k alUhat apply): 
D .. Edircatjm sHsiaa(s)... . 
D Ozt.:.site ai!rciSe . 
0 .Home-based elD!lcise JB>gra'JD 
a·-~~····· .. · ..... 
a.·~-~~wcGmu1t 
o~:mDSidt, .. ····· .... · 
o ,l)iabeles~r&emI·arOimSult 
t:is~~,ar~}~~Immlilt 
2 ... -~~,~~~l>ecl:, ........ •• ----
. ... . . . . 
. t·.· ~ofsessions~Idect ____ or:: 
Ar~~~~~~ 
a:·.·,N0t~m·dlad 
;. : :·::.·:--:: ·-:·-·.;:·.·· .. :::·:· ·. ···:: <::_:: ·.~::: :: .. :::>,:. : . 
dd 
\lf"ci~san~~ :·:·· :·.· 
DllDJJl . YYY'J . · .. 
chart? 
; o· Yes, please si>ecify~ 
6. Rist Factms· 
Yes No 
C J"ypel I CITJP.e n 
B D. HbAlc°4 I I 
dd I mmm.1 Yaw 
BMI(ki¢n2) 
0 ·Obesity (BMl>30) Date assessed I I 
0 I I 
IIDL 
0 0 
IDL 
Date assessed I I 
dd 1 IDDllll I mr 
CR-CDMProgmnEvaluationD/C. Vasi.on 1. September 1, 2010 Page2of3 
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·dd mmm yyyy 
8. . D1sc1mge &m::ise Stress Test 
a. Completed: No Yes, date: 
b. PeakMETs: ____ _ 
c. PeakV02:: 
dd mmm Y'J'/Y' 
-----
:·1~~·.~~~··~··~.~.toatherbealtbcare~s)invoJved•mpatieofpre'! 
C~· 
.u ... ~ Media.· .. ··. - ..• 1iODS .. · at~ Cc.beck an tbahpp ... lY.· ).: o Ac:Elnmbitar.i'· · .. ·· ···· ·. · · · er~ 
c ~~ Cl .Betl-b~ O:ASA. .. . . o:~ 
CJ CaJ.+.mtaganists CJ ·.··Niliates (oat PRN) 
c :·Staiin Cl . ARBs 
011:.:.~ CJ~ 
C LI.-:Diaitinieacid C Cr-nnadin 
c .ll."'""115iildlogs 0 Hepmn. 
c DimetiCs CJ BR:T 
C ~m CJ .Imulin 
.. ticlaPidine Cl ·Oral hypoglycaDic 
c Other mh-p1atelet c AntHnfbmmatmy c ~Replacement Cl Other: _______ _ 
C·.~·. O Notn!pOrledmclmt 
CR-CDMProgmnEvaluationD/C. Versionl. September 1, 2010 Plge3of'~ 
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Appendix E: Initial Survey Demographics 
SEciiONA: YOUR SOCI~DEMOGRAPHIC CHARACTERISTICS 
L What do you consider to be your racial/e1lmic background? Please check !a one (11) of ihe 
{Dllowing boxes: 
a·. Nor1hJ\merican (e~~ Canadian, American) 
Q Frmdi (not Ftmeh-Caoadim) 
a :Briti$b. Isles (~g.~ IhitWJ.. SCottish. Jrish) 
a .weslettl~~{e.g.,, AJJStrian. Belgian. Gennaa. Swiss) 
a. N~ElitQpean(e~g.)>~1wm,Finnish) 
0 ~E~(e~t.~Ub,ainian~Potish,.Czech) 
a, s<Juthem. ~UrOpealic(e.g? Gie.ek, Dalian; ,Spanish) . . . [] JewUish .... · . . .... . . ·. .·· .... 
a A&itan; 
d'.An.b 
a.w~A~sm(e.g,,~~;;11:~> 
I:] .. ~~l(e.g..,,~Jnd.ian. PIJrijam,~) 
a E;lst Oi Si>'@i &st Asian (e.g,,'. cmDese; Filipino> Japanese; Vietnamese. Thai. Laotimi)': 
d'. ~(~~ ~~5 (".ealsDter, P;acific Js1aodes:s) a< CaribbP.8n . .. . . . ..... · .. . . .. . . 
c:i 'I.a.tin;·~~ Somb.~ 
a Abonginaf(e.g~.·Metis,111uit) 
a Otber(Spemy: _________ _ 
a .Multiple cultma1barkgrotm,ds{spedfy: _________ _ 
2~ Please rate how comfortable you are speaking, reading and writing in EngWm: 
a Not e:omfort.a.bte · · · · · · · · 
a ·I can get by~bOtammore comfortable using a language other than Eng1iSh 
a Fairly comforlabJe 
a Very oomfortabJe COIDllIDDicat.iug in EogliSh 
3. What is your marital status: 
a Manied/common.-Jaw 
a Separatedldivoreect 
a Single 
a Widow 
4. What is the highest lewel of education you have completed? 
a 1ess than grade 9 
a less than high sc::hool 
a completed high school 
a . some college QI' university courses 
a completed college onmiversity degree 
a Graduate SchootJ&ofessiaml Program 
CR-CDMProg Eva!- Intake Survey 
V6-0ct ti,2011 2 of20 
56 
.5. Which opticnbest lliatcbel YOIU" .em!!! work sta1us? 
a foll-time woik 
a.• part-time work 
a· fblbtime c::ategiverorhomemam (inside your home) 
a. unemplojed 
a receiving disability 
a .:retired 
a other: .. _______ _ 
6. Which optitm_best'lriakheS yam~ wade status? 
a fun-time wadi. , · · · · · 
a. part-tinlewmt: : 
a full~ caregiVer or homemaker (inside your home) 
a.~~ .. 
a ~vmt disability 
a letiled 
c1·otbfi.r:._:. ______ _ 
7> ' ' ' ~ .. ' ... · '. ' .;a_.;_? -What JS tOOay s Uill.C_ ' 
............... : 
' J&IU.J· 
MontJi. 
Yeu: 
CR-CDMPmgE~ Imake Survey 
V6-0ct 12. 2011 3of20 
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Appendix F: The Duke Activity Status Index 
SECTION B: UsU~.\LACIDTI'IES 
Instrudiom: The following cpstions have to do wi1h your cmrent activity statns. 
Please~ @ or@ in response to eadi question. 
CR.-CDM Prog Eval-ln1ake SiJnrey 
V6-0ct 12,, 2011 4of20 
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Appendix G: Godin Leisure Time Exercise Questionnaire 
SECTION C: EXERCISE 
l. Duriog a tjpical 7:.Day period (a week). how many times on the aw.rage do you do the foll~g 
kinds of exercise form.ore than 15 minutes during yoodiee time (write on each. line the · 
appropriate lllJIDbel')~ 
Timt'S per week 
a) STRENlJOUS EXERCIS".E 
(HEART BE.ATS.RAFIDLY) 
· ~: lumling,jOggirlgJ1ard1cmg clist8nr.e.bicjding. aoss 
amnfryskiiDg.~Ql"oUsSWi•ntl)i~ . 
. IJ).. MODERATEE.~RCISE 
(NOT EXllA,U~G) '. 
{Fxamptes:°'DSt~ easybicjding. easy s~dancing) 
c) .· , MILD l:XERCISE 
(M.Th"lMAL:ttfott".I) . . . . . 
(F7amples:·~·bowiing;.:goif:.easyw.illcin~ 
. . . . , : ~.. ' . . . . . .... 
2~ DUriag ~,ijpital 1~Daj Jmioci'(a~). m. yam Jeimn; ~~ ~ oitm do you engage in any 
regular actiyity.mg~ugli to ..¥mkU., a sW~~t ~beats RPidly)? 
·oFrEN 
1. ci 
CR-CDMProg Ewl-Intake Survey 
V6;,.. Nov'9, 2011 
SOMETIMES 
2.0 
NEVERJRARF.LY 
l.0' 
5of19 
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Appendix H: Health Promoting Lifestyle Profile II- Nutrition Subscale 
SECIIOND: NUTRITION 
Imtructiolls: ThiS •qDestiosmaire ccmlaiDs ~·about your present persooal lllltrition habits~ 
Please :respond t() ea.ch item as accan.teJy as possible, and tly iiotto skip any item. IndK:ale;dte 
frequeocy With which }'PU.e:ogage in eaCh behavJ.Or.by cirding: 
N foinever, S fiJr s0mf.ti1Dei. ()for often.. orlUm rolJtinely 
. . · · · · · · · · · .· · · · · · Ne~ Sometimes Often ~tinely 
CR-CDM Prog Ewl- Intake Survey 
V6-Nov 9, 2011 5of18 
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Appendix/: Morisky's Medication Adherence Scale 
Instnictions:• ~mu~-~bavet.Odo.withyomprescribed~ 
~~ .@0r@ in~toeachquestion. 
CR~ Pmg Eval-Intake Survey 
V6-Nov9,2011 6ofl9 
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Appendix]: Smoking Assessment 
SECI10N F: SMOKING STATUS 
1. Please describe your smoking status (please check ONE box): 
a · 1have neVa-smobd (skip toSectiOn.G) 
a· I cmreody smoke 
L, How many cigarett.es per day on avenge? cigarettes per day 
.b.. Fa£1Ww IDallY~have yousmphd? years 
C. .Do yon.find' it diffiaJlt not to smoke in si1umians where you woulh.onnally dO ~? 
aYes aNo 
d... line you. tneci m st.o]> smo1cing but found JUD cou14not1 
·. · a-ve.s·aNo · '· · .. ··. ·· · · .· · · ·· · 
CR-CDMPmg Eval- Intake Survey 
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Appendix K: The Patient Health Questionnaire-8 
SECTION G: YOUR MOOD 
Ovrr the last 2 weep, how oftm have you been 
bodttred by uy of tile following problems? 
Not at all .Senral :M.oft!·thua N~dy 
dsya half't'h en~·tb;r 
days 
2 .. :3 
2 .:~ 
2 .·~ 
lfyoa checW ofF .!!I problmas, llDW ~ laan daeR pmbJEm made:it for :ro• to do ;yov work, tW C1lft of 
·1mgs at homl\ Or get aJaag 1l'ifla Diller PffPJe? . 
N4lt diflkuJt 
at all 
D 
CR-CDM Prog Eval-Intake Smvey 
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Appendix L: The EuroQol-SD Quality of Life Scale 
SECIIONH: OUALITY.OFLD'E 
F« eadlgmopbelow,, please choose one statement that best describes 1he state of yam gen~ he~ 
today •. PJease c:hedr the box~ that matches.your answer_ .. ,. 
A. Mobility 
a ·I have no problems walking about 
a. I have someJ>fOblems.wallcing about 
a I am confined to bed 
B. Self;.;Care . 
a I have no problems With washing or~myself 
Olfla.ve some prob1ems widJ. washing m: ~·myself 
p. lam Unable to•lvasli or dresS ul.yse1f 
c~ USUal Adjrit:ies (e~g~ w~ ·!ltiidy~ hOusew~:famifyor leisure activities) 
a;t~k.Ji,<>~#~~yusua.{adi\rities. .. . .. . 
p I have ~pi01>1ems With perrmming .nyusua1 actMties 
a [amUDBbleto peifmmmyusual activities 
· n. Pa. and Discomfort; 
a, ··r~ve'!lC>pam « disccxofori 
a rmvellloderate paiBoidiSCommrt 
a· Ihave·~·p;un·~~ 
E. Amiety and, Depression 
a I am not anxious« depressed 
a I am. moderately anxious oc depressed 
a •ram eXtn!mely:auxiollS m depressed 
CR-COM Prog Eval-- Intake Survey 
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To help pe:Qplua:y how good or bad a health state 
is, We baVe c:h:nm. a>scale (ntber Jh a 
thermometer)·•ao.which fbe.best•sla:te· you can 
imagine is m.arked.100 and the worst state you cm 
iinagme ls IWi1ked 0. 
We wcuhl like you to imliclte on this scale how 
; gc>oclor~yC>urownhea11histoday; m yom· 
~On. PJeaSe oo'thiSlry ~alilie ftomthe 
.; box~mi•t0'whicheverpoint.oa.1besca1e 
indicates.how good· or bad yaorhealth· sta1e is 
. today~ 
CR.-CDM Prog Eva!-- Intake Smvey 
V6-0ct 12,, 2011 
Your own 
health state 
today 
Desi! 
Ima~!.~~~. l)Pjlat6\~)fe 
tl'jijj 
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Appendix M: Godin Leisure Time Exercise Questionnaire & Exercise Location 
sECTIONB:·EXERCISE 
J~ Immaga typi~ 7~DaJ,period. (a.wt!ek), how many times on the average.do,ymdo the follow.mg 
· kinds of~iie fof more tlGiialSnlinutes during yo11diee time (write· on each line the 
appropria1e·m1mhsl 
llj··~9t1StxER.ClsE 
(B~ARJ71l:EA'.I'~ ~LY) 
Q!~P'eS=·numU,g;foWi&•~•1qng~·~· 
.. ~~,s~i~·~~ ·· 
.t)·'lt{ol>~fi.:'t.~~E 
... (N.()T~V~'fl. . ....... · ..... · .... . . 
~=•fim.t.wallciDg..~1>i.c:ycliDg;··~··swimming. 
~~i11g)·· .. . .... ·. ······ .... 
~)•·1,iIID~· 
·!:~JN·~~,.~l{~~ 
Times per week 
'2~ : During a tYi>~ral 1.:.Daypeftot1; (a weel;}, ~yCJDi lelsure time» how often dO you engage in any 
~~vify~enougbto~m aP a mut(heartbeats ~y)? . . . 
OFI'EN 
La 
SOMETIMES 
2 .. a 
r , 'Where did you exercise in the last 4 months (please cbeck one)? 
a At home or in my cmmimmtyQNl.Y 
~a I participated in home-based cardiac rehabilitation 
a At·mpenised .cardi3c :rehabilitation ONLY 
NEVERJRARELY 
3.0 
Cl At hOme or in my commmity AND at supenised cardiac iebahilimtion 
a Atanotbercardiovascolarrehabilifation progtam. Where? _______ _ 
a ·I di4D't exercise anywhere 
CR;,.ffiM Prog Eval ~ follow•up Stllvey 
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Appendix N: Exercise Plans Post CR 
SECTIONC: EXERCISE AIT:ER CARDIAC REHAB 
1- Where do yon irderid to eercise no\V that yum cudiac rehab pmgnm is mrer:(please<~ It! 
all that apply)? 
a.·Athome 
a In mymrmmmity(ez:ampte: laca1 gym or commouity cen1re) 
Cl' ~?pJeasespecify: __________ _ 
a T4':m':fpbm to exert:ise 
, 2:- tfyou p~to exercise at bQme Only. have }'ooplanned What liild of' exemse you are:i>ing to 
, do? , , 
Cl Yf5.p)9sespecify: _________________ _ 
ti'No . ' · ... · ... 
a ·N<rt ~licab1e 
··3~-~~~tm~~.niarorDrmniitytacility~doyoumtmdtojoiD~·'tlatyma 
·a·Yes 
tJNo 
'tl'~m~Je:· ... 
CR-CDM Prog Eval~ follmvup Smvey 
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Appendix 0: Health Care Utilization 
SECilONI: USING MEDICAL CARE 
l:mtnimom: .· 
'We wo11ld ~.to bow alXmt thehealih professionals yon saw daring die last 4 moaths BECAiESE 
OF YOURCARDIOV~.\S-CULAR HEALTHdtwillbe easier 1o .answel" if you refer::~ a Cal¢"~ or 
. ·. · · fttJrM:aint Jisto!lwhich .· · ······recORI·• · .·· ·' .·· .··' ·' .·." iDtmefits: If. . · did: not 1r...-. a recant. ~:io ~.·. her 
.3PP°' ......................... :you ......... ~ ~...... ·.. . you . . ~ . ·. ·•. ~, ............... ,,,_ 
ifau.y appointlDentS ~ on<tp1ear s.peC#ll .diJ,~ SUCh, asyaur birthday:; 0r the my of~~:~ 
}'~ims\Vef tbe questionsbe1<Jw byenterillg ~mmiberof1im5in the past4 ~;tJiat~i~ 
1, ~~ .. ~tc>tt.e.•~ 
......... ;.~11-
t Haveyml'UperienCecl.my of~ foll.Owing he3rt pr:oblems or pmeedores ill the last 4 mo!Ults't€P~ 
. ~.a all~ apply}: . . . . . 
. . a He.artAttack·· 
. a :Angma . '• .. 
0 Angioplasty (Stent) 
• a Bypass Smgay 
a .Val\r~Sucgefy 
a He.art Faih:mL 
a Heart tl:lo.splmt 
a Pacemaker or implantable c:ardioverter defibrillator 
a Stroke 
0 Peripheral VliScWarDisease 
a Ablation . 
a Left ventricular assist device 
00ther7pleasespecify:~~~~~~~~~~~~ 
a None of the above · 
CR-CDM Pmg Eval-6M follow vp Survey 
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ID#: 
6. Have :You experienced any of the following diagnostic tests in. the bst 4 months'! (Please check l:tJ ~ 
·that apply): 
Cl ·X-Ray 
Cl Electrocardiogmm (ECG) 
Cl Blood test 
Cl· Urine test 
Cl CTScan 
a• Ec:hocatdiogialll 
Cl Stress Test . 
Cl Other~ please Specify: ____________ _ 
Cl None of1be aoove 
:7. How much of your 01"ll money in to~ did you pay for 1hese hea11h cire visits (eg., trmsportation, 
.· . ·• ·.Pamn&food.. lodf}lig). including the maney paid by anymie who aecompaoied you? 
. . Cl None OR.enter amoUilf::• S __ _ 
·~-How,~<~~~ ~ted with~¥aJtb•~ue visits C~traveJ.. waiting, etc..)? 
hams 'Di ~bd' 
~-----' 
9~ How nmCb. ofwlir·cntn iDCuiev. in totat dia yoti P3Y £m }'Our cardiac ieJiab ·visits c~" llampartation, 
· · · padriilg, fOOcij, ilicliJ@.lg ~ m.aneypaid by an.yone who KcompaJlied }'OU'! 
Cl None OR.eoter amotmt: $. .. ·' ' . . . . . 
___ hcmrs in to1al 
lL In the last4 months, who USUALLY accompanied you on the visits .to cmliae rehab'! 
Check (i) all that apply. 
Cl, Nobody;! wmally went by myself 
a Paitner · · 
Cl Son,, daught~ or grandchild 
a . Sister~ brother; ftiend, or D.eigb.bom 
O· Vohmteer 
Cl Paid homemaker or caregiver 
Cl0tber7 p~uespecify_· ____________ ~ 
1 lb. This person's age is: vea:rs. 
1 le.. This person is: D Male. OR 0Female 
CR-CDMProg Eval ~follow up Survey 
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Appendix P: The Cardiac Exercise Self-Efficacy Instrument 
SECI10N C:' 001\'T.IDENCE 'WITH EXERCISE 
.Howmoch confidence doyouhaVe·abaut·doingeach oftbe behaviors listed below? These are'notr 
quesiions about what you are mpposetl to do. They are questiaos about what you think you.can 46. 
CUc1e tbe·tetters•tbat:Show JUur•beliefs. 
Loes 
A·• B 
A B, 
A :B 
A B 
A B 
A B 
A B 
A .B 
A B 
A Quite .. 
a Lot 
c 
c 
c.· 
c 
c 
c 
c 
c 
c 
B C D E 
·~----------------~. Very CONFIDENCE Little 
... . . 
Howm•h confidence do you ha.ve ••• 
littl~ 
D E 6) CSCooling down~ after-exercise. 
D E 
D. E 8) EndmiDg strmDous exercise. 
D E 
A B c D E 10) Knowing when I can increase my exercise level 
A B c D E 
A B c D E 
A B c D E 
A B c D E 
A B c D E 
A B c D E 
CR-CDMProg Eval-~Survey 
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Appendix Q: Patient Assessment of Chronic Illness Care 
SECI10N J: PERCEPTIONS OF YOUR CARE 
· Staying healthy can be difficult when yon have a chmnic. condition.. We would tie to leam 
abouUbe type of help with yam: amditim you get from your health care team. 'Ibis might 
include your egn1ar doctm, his or her muse, or physici.an"s assistmt who ,1re3ts your illoess. 
Yom answers will be bpt .confidentiat and will not be shared with your ph:ysician or clinic. 
Ore · the ast 4 month~ when I reC'eiYed C'aJ'~ for my heart conditiont I was: 
B4.G:ivm a writtmlist of things I 
should~· to impmwmy health.. 
. ·Bet.Shown hoW what I did to take 
. care of myself influenceA my 
condition. 
BR.Helped tn set specific goals to 
improve my eating OT exf'lcise. 
BlO. Encouraged to go to a specific 
group OT class to help me cape 
with my cbro:oic caoditian. 
CR-CDM Prog Eval -6M follow up Survey 
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ID#:_ 
- when l received ca1·~ for my httart condition~ I was: 
None of ALittle Some of Most of Always 
CR-CDM Prog Eval-6M follow up Smvey 
VS ":"November 9, 2011 
the time of tile the Time the Time 
TDDe 
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Appendix R: Work Status 
SEC110NK:,\\1URK STATUS: 
· L Whichopfumbestmatcbesyourcmrentwoi:k status? 
a. ~timewoik . 
a part-"timewod:.. . . . . . . . 
a ~caregiyerorlvJJnetnalter ~deyourhame) 
a~ unemployed . 
a ·iecei~ disabilify · 
a retired 
a o11iec: 
.,...--------
2> Whidi CJl'tionbeif matcbel Y~ desired wori: stat9s? 
'a ·fulli.fim~.Wc>lk · · · · · · · · · · · 
·~ ::::wo*..m or homemdei,(ills.icle , home) p ·IJll'~b~ '. . . . . . . . . . . . . ·. . .. your 
.a.~Villg~l>ili1f · a retired. , . . . . . . . . . 
•cl other.' · _....._ _____ __ 
--
J .• J:)fm!!!{tmf!Jil~t4r.n0Btbs, ~Y¥~ ~ diffiCulty woikiogat yoDr paid employment,JHcaue:ot 
vour,cantiovastnlirheatda er its treafiM.nt? 
o•·•,1·wu'·,,11.#1.p~:m.-.~ea,driDrig'fh¢••11St.4montbs 
.CJ :NQ~Jll>.:difli~'~oikingbetameofmy•bellth · 
a YES, lhad.difficDlty,working , 
3.b. Ifya,; whatWutbetomitimeyoli:haddifficultywo:rking: _. __ dayS and/or __ . ·mmn 
kBy approximately' whatpereent was yoorwod:ing capacityednced.during this time? __ % 
4_ Did you need iieJp to c1D your nnoaia Wo1t ceg.> lioUehold Chores, calegiving. :numing emmcts> in· the 
last 4 mmitbs? 
a Yes 
a No 
4b. Ifyes.. whatwas the to1al amount of time that other people did choies mryoo in the last 4 
mo~·~payfromyou: 
0None OR 
4c.. If yes,. what was the total amount oho.r mm monrcv you paid people to do chores f.oryQu. in 
the last 4 months: 
0 None OR $ ___ _ 
CR.a>M Prog Eval ~follow up Survey 
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Appendix S: Assessment of CR Participation 
SECTION M: C.ARDIO\.·AscUI.AR.REllABiurAl10N PARTICIPATION 
lastrudiou: CmliovaswlarIPhahiljb!ti~ (CR);is mompatimtprogmm of stmctmed.exmcise1and:·~ 
tomamniDr: your recovery_ Pleasedlec:k the ~box in response to each qaestion.: Ifyuur~ecl! 
.answer bas an·arrow reading to another~~ the questions inibe attached box. .Please mmmywri#m aJJSWelSclearlf.- ,. . . .,. ,' . . . . , 
1.• Didyoa·atteod•a·~.rehllbiliiationmesSmmt(inbkeappointment)1 
tl .. Ya ·~ I• (lf:Yes)1.Whei¢? 
•••··. · .. · .• rHoWloanynlimdesdidyot1takeyautotmvdtbeie~way?. · .... · .. __ mms,·. ' ON~~ .··· ............ ......... . .. . 
I . (Jffl<j>~pot1 
:C:fY~ --~> · (If Yes) LWlmttype of'pmpm did you attend? (please 0 one~) 
, . .. . [] .. , \VoiDerH.mlybospitai.bued 
· a··• ?den~womenhospital-based 
·c< H~teci . .. .. . 
z·~briW .. iiWiy·Weeics·•passe,d betweenbeing diSdmged 1mm1mp1t..J; 
Ind starting tile ~vasCllJar rehabpmgmn? wb 
3. Did you consider this to be m acceptable or unacceptable 1eogth of time to ·wait? 
.~ :=1e1 ... WhJ1_ .•. _· ._··~-------.....1 
4 •. Appmmoa:tely ~ peromtage of Vasmlar rehabilitation sessions did'you 
complete on the phone or at the hospital? · · 
-----%of sessions c:ompJeted 
-1 (IINo) Whymit? .l'leue be aupecific .. jW cm. 
CR~M ProgEval-6M follow up Survey 
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Appendix T: Cardiac Rehabilitation Barriers Scale 
ID#:_ 
SECTJONN· C;\RDIOfASQJLARRW\BUJIATIQNBABRffiB§ 
The following quesbons•aSk•abouf .. SO!Deofthe filctms infloem:ing.}'OUI" attmdmce:at cmtiac rehabilitation 
sessions~, Pleue aJiSweJ" an of the nemou On thiS page regardless of~ you attended or did not< 
attenda·amtiac Rhabili1ation mognu:n. 
I di.I~ attaad a arditt ~proi;nm, oririclid attead,I 
mimd llDllie ~ beCU-: ·, 
. . . . . 
.. t ·--~or~ (e.g.;Ds:it~ mJ'11ir ~ta0&rto lr.m!I) 
··2 ~~-ofc..ast(~g..pmmg,~) 
3 .... cu~~ce:~~ID#~tzmspcatdiaD) 
4.·.'.·o!~ieslimisrliiJjt!,.C, ce~~ving) 
?~ .,ldidn'~~ibDat·~.(~~~~dicfn~t~IDe .. aboutit) 
'6. ;;.I -~tDeed~ (~t.. &ellRD,hUdproblmi tmdi!d; not sBioas). 
~ . . . . .· .... : .. · ·. . . . .···:;· . ·. . ... ;. .·, . . . 
:7,;·~·~.1~~-lllme. .. ~n;'Y~ 
tL.:;SINl!le~• 
.... ...... ... . . .. .. . .... 
··9~;.iw~bimgcr~. 
··-. .. . .. . ..... 
lll,,.:mvEI(e,g.~~ ~,, cotbgej 
11. -~,orfu:ae.~ Ce-i.txJobll5y,~cimtime) 
i2 : .. ofd~~lnlities ' 
13~ __ _J -~t line the~ 
14. ·: .oiher bea1th piVbleaU Pamsit me mm,. gamgCspecify: .) 
15 ... J :amfuo old 
16 ... .my dodm did not feel it~ 1ll!ICe!5iiy 
17 .... :mmy peapJe vilhh&lth problems -~t gD, and iliey at? fine 
18. ·-. I Cillllllilmgl! my healih .pmblem Oil my own. 
19 .... I think I was ~lmt tlie.n!bb pmgmn didn't c:mdad me 
20. ... it toak too Imig 1D pt n:f'erred. md inlD fhe prognm 
21 ... J prd!r to tah care of my healdukme, not in a gmu:p 
22. Ot1JK~(5}fm-natat1191dinga·~~OD~ 
CR.-CDMProg Eval-&f follow up Survey 
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Ii I Iii I ft 
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D D ·o DD 
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CJ.· D D DD 
D .o D DD 
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DD DD D 
DD DD D 
DD DD D 
DD DD D 
DD DD D 
DD DD D 
DD DD D 
DD DD D 
DD DD D 
DD DD D 
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Appendix U: Survey Non-responder Cover Letter 
~. \\Jrk'tllmtr.I~ ~ · 
umma,Bc.llhNawmk ~~~,,~J!~~::~!rr~~n ·~ ~.~~~.T,~}.~.~~~ 
_._. ..... _ _.........,.... 
«Date_of_ Discbauge _Suivey _ Rq>Jacemml» 
(~ <CF"int NlllDeD «Last N111e> 
~··A~- -
«(jity»"«Provinte> ~ostai--Ccidf» 
' . .. .. . ... .. . 
:~E: Chronic Disease Management Evaluation Mailed Follow-Up 
survey 
. . .... 
·:· Dear. ~sabitation» «Last,...NlllDeD: 
. AboDl ram Weeks 3go Ismt a sm:Wy tOJOil that aS'kedhawym n mamging :y0m lie.alth.. To the best or 
~~lt'saat~~~. . . . · 
- ... . . .. .. . . . 
• mmmeatsofpeaple~hm!. ~nspcmded~ii wide vmetyofamwl!ft~dieir 
ezrenm .. ,... Stiying adivuiid ea.mg~~ widJ.p>tl!ntial bairiss that niay have.hinden!ddu!ir 
~We tlllnkthe in{nrtn:atim mnededmantheseSllm!JSm!! ~tD be W:rymefalto~ 
secoDdaty ~pRlgr.llllS:im patiimtsluiib. dDUiDc caaditiam. .. 
We are writingap'in became of the impmtmce &It yam Slin~ ms fDr lielping to gl!t ~ resn1b 
amHeeidbadt. lt's mly by liearing from neatly evayane &am the piagram dmwe an be sme,fhat the 
results are tmly~ · · · · · · · · · · 
ACammi!Dt cm am sm:Wy poc:tifuu:s:. a .mn.v idmtifiratinD ~is pi:inted on the sun.'1!.f so that we 
C21lchld your mine off of themoaling list.when it is.mamed. '!be list of Dmll!S i5 btel-desaroyed 50 tmt 
:indiridual·names rm Dl!llH be~ to tlM! :resubs in any 'Way. Protecting the cnnfidmtialjty of 
peopll!'s am'liR!l5 is very impmtaut to us. 
We hope tliat ycmwill fill out ;mrJ mtumthe 5lllVl!Y SOOD,, bat if fiJr ;my masm you.~ JJOt to answer it, 
please li!t us bow by.mturnmg a IJJOie.m blank survey in tlie erJclosed 5tamped enwlape. 
lfyau hon~ ;my·questiom about the sam.-ey er its purpose. please f2el he to coabd· our study 
eocmtimtnr, at (416) 736-,.2100 ext 20575. 
(\ r"'"" . 
'.·j . , krAJ('· 
'·· • J 'v1 ""' _.,, 
Dr. Shary L Grace 
Univenity Health Netwodc,. Yark Univenity and Y mk Central Hospital 
CR-CDMProgEval V3.Nov9, 2011. 
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Appendix V: Survey Non-responder Telephone Script 
-Telepbone COntact Saipt forNmr~to the Cbnmic Disease 
ManagementProgramEvaluation 6 and l2-Mon1h Follow-up Smvey 
Rm.ttda • .\mstmt(RA): "Hello :my:oa:llJe is [enter IWIW]. I am 1be stuci_y' comdinator 
fm mr IeSellICh ew.luating the dmmic disease managmeit prognn1evaluation. Duijiig 
the.last &weekl weh.llVe.~·y()U~ ab0Urciurprognmr~11p.s.mvey .. It. 
ioclmes~11JatWiJlbelp1JS~ 1he cplity o(:selvices~We ~ve not yet 
rec:e.wed a~ survey fuma yoU, sormC:alliDg to See if:you'have my qaestiong!' 
An.nwir any quirsi;onsJi1ul.•asi7.s impol1lmc8 of Obtaining IBISWllrS/rfmt aH 
plirticipaJm'llHms»iw~nmlls. · · · 
Rese.Vt•~taJit.(RA):."WcJulditbe a1l right if we mqiletedtbe~ now owr 
the~?Aliythmg ···· .·· .·. · .. vrillbekept ccmfidpntial" 
..... ·.············ .. ··.···• ... ·~.~ .,,. ............... ··· .......... · ... • .. . 
'lf P'.~ ai&t~~ RA~(;o tiwug1r'tjU~ RBCrmJ~ 
/f P ~·?lo "".1:. Jl.4: '..Would}'ou like~tn :receive a :repJacemmt smvey by mail. ar is 
there a tiine Wiim lcould can bad:?"' • . . .. . . .. . . . . . . . . 
Rst:Oni .. ~•fiJnB·dndcaJl btlckOTTGmrd q'ucaoftilaila 
. . . - . 
Q' Psays thy don YWis.lt•to compllltB ~at all: JU: "'J.1haJJkyon fnr your time.. We 
will take your name off of aurmailing~ and this will be the last CODtad we make with 
you."" 
CR-CDMProg Eval VJ.. Nov23, 2010 .. 
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